$25M ProspectusThey’ve left it open as to when they may issue shares. Have to believe that they wouldn’t do it without some major catalyst to minimize dilution. To take products through clinical trials is many millions and well into the next decade. I’ll note the CEO hasn’t sold a share. So if he pulls the trigger, he’ll be eating his own dog food along with the rest of us. Definitely behaving like a micro biotech. I suspect that 32M royalty payment isn’t going to happen due to the financial state of their payor.